14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AKRO vs STOK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Stoke Therapeutics, Inc. (STOK) on higher Unified Composite conviction (60.0/100 BUY vs. 55.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while STOK wins 4–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus STOK at $26.81 (N/M Forward P/E, -913.2% operating margin).
Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. STOK 55.9/100 HOLD) and 0.90β · 2% Vol risk profile, whereas STOK leads top-line expansion (+5.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs STOK. Trailing 12-month operating profitability (AKRO 0.0% vs STOK -913.2%) and valuation multiples (AKRO N/M vs STOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.8B market capitalization and -913.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKRO vs STOK Key Questions & Quantitative Answers
As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Stoke Therapeutics, Inc. (STOK) on higher Unified Composite conviction (60.0/100 BUY vs. 55.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while STOK wins 4–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus STOK at $26.81 (N/M Forward P/E, -913.2% operating margin). Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. STOK 55.9/100 HOLD) and 0.90β · 2% Vol risk profile, whereas STOK leads top-line expansion (+5.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
STOK leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with STOK at +5.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (100.0% gross margin, -913.2% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $28M for STOK. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STOK.
STOK screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas STOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 58.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus STOK (-73.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, STOK carries 63.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.27x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.83β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.